Australia's most trusted
source of pharma news
Sunday, 08 September 2024
Posted 26 July 2024 AM
After a dramatic decline over the past decade, the lipid-modifying agents market is now set for a "spectacular revival" according to analysts, driven by two innovative therapies - Novartis' Leqvio and Amgen's Repatha.
It's predicted that these two treatments will spearhead the market's resurgence, bringing it back to prominence by 2030, according to GlobalData.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.